Key result
Safe-dose thrombolysis plus rivaroxaban in patients with symptomatic pulmonary embolism significantly reduced pulmonary artery systolic pressure from 52.8 to 32 mm Hg within 36 hours (P<0.001).
Why the study?
Does safe-dose thrombolysis plus rivaroxaban improve outcomes and reduce hospitalization time in patients with moderate and severe pulmonary embolism?
Population
98 consecutive patients with symptomatic moderate and severe pulmonary embolism
Design
Cohort
Follow-up
mean 12 ± 2 months
Authors
Loading...
May reduce PASP rapidly in symptomatic PE without bleeding; leaves open need for randomized confirmation before practice change.
Cohort (n=98)
Does safe-dose thrombolysis plus rivaroxaban improve outcomes and reduce hospitalization time in patients with moderate and severe pulmonary embolism?
p-value: p=<0.001
The combination of safe-dose thrombolysis and rivaroxaban appears safe and effective for moderate to severe pulmonary embolism, significantly reducing pulmonary artery pressures and facilitating early hospital discharge.
Sharifi et al. (2013) conducted a cohort in symptomatic pulmonary embolism (n=98). Safe-dose thrombolysis plus rivaroxaban was evaluated on pulmonary artery systolic pressure (p=<0.001). Safe-dose thrombolysis plus rivaroxaban in patients with symptomatic pulmonary embolism significantly reduced pulmonary artery systolic pressure from 52.8 to 32 mm Hg within 36 hours (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: